Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 8, 1999, Pages 1109-1114

  Dammann, H G ^a   Burkhardt, F ^a   Wolf, N ^a  

^a Wissenschaftliches Institut   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ASPIRIN 100; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; ENTERIC COATED TABLET; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL MUCOSA; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH LESION;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DUODENAL DISEASES; FEMALE; GASTRIC MUCOSA; HUMANS; INTESTINAL MUCOSA; MALE; STOMACH DISEASES; TABLETS, ENTERIC-COATED;

EID: 0032816044     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00588.x     Document Type: Article

References (40)

1. 1 Adams HP, Bendixen BH. Review - Low- versas high-dose aspirin in prevention of ischemic stroke. Clin Neuropharmacol 1993; 16: 485-500.
2. 2 Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. 1. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. II. Maintenance of vascular graft or arterial patency by antiplatelet therapy. III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Br Med J 1994; 308: 81-106, 159-68, 235-46.
3. 3 Miller VT, Rothrock JF, Pearce LA, et al. Ischemic stroke in patients with atrial fibrillation: Effect of aspirin according to stroke mechanism. Neurology 1993; 43: 32-6.
4. 4 Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J 1988; 296: 313-16.
5. 5 The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 282 mg a day) in patients after a transient ischaemic attack or minor ischaemic stroke. N Engl J Med 1991; 325: 1261-6.
6. 6 The SALT Collaborative Group. Swedish aspirin low-dose (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991; 338: 1345-9.
7. 7 UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. Br Med J 1988; 296: 316-20.
8. 8 Silagy CA, McNeill JJ, Donnan GA, et al. Adverse effects of low-dose aspirin in a healthy elderly population. Clin Pharmacol Ther 1993; 54: 84-9.
9. 9 Weil J, Collin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. Br Med J 1995; 310: 827-30.
10. 10 Naschitz JE, Yeshurun D, Odeh M, et al. Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease. Am J Gastroenterol 1990; 85: 408-11.
11. 11 Henry DA, Ostrapowicz G, Robertson J. Drugs as a cause of gastrointestinal disease. Baillière's Clin Gastroenterol 1994; 8: 271-300.
12. 12 Lanza FL, Royer GL, Nelson RS. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric coated aspirin on gastric and duodenal mucosa. N Engl J Med 1980; 303: 136-8.
13. 13 Cole AT, Hudson N, Liew LCW, et al. Protection of human gastric mucosa against aspirin - enteric coating or dose reduction? Aliment Pharmacol Ther 1999; 13: 187-93.
14. 14 Dammann HG. Gastroduodenal tolerability profile of low-dose enteric coaled ASA. Gastroenterol Intl 1998; 11: 205-16.
15. 15 Hawthorne AB, Hurst SM, Mahida YR, et al. Enteric coating of aspirin eliminates gastric mucosal damage despite inhibition of prostaglandin synthesis. Gastroenterology 1990; 98: A56 (Abstract).
16. 16 Delcambre B, Defrance D, Sulman CH, et al. Comparaison de l'éfficacité et de la tolérance de trois présentations d'aspirine. Gazette Méd France 1976; 83: 4091-8.
17. 17 Mielants H, Veys EM, Verbruggen G, Schelstracte K. Salicylate-induced gastrointestinal bleeding: Comparison between soluble buffered, enteric coated, and intravenous administration. J Rheumatol 1979; 6: 210-18.
18. 18 Miclants H, Veys EM, Verbruggen G, Schelstraete K. Salicylate-induced occult gastrointestinal blood loss: Comparison between different oral and parenteral forms of acetylsalicylates and salicylates. Clin Rheumatol 1984; 3: 47-54.
19. 19 Houk RW, White JA, Liu WM, et al. Gastrointestinal blood loss in rheumatoid arthritis patients receiving plain, buffered, and enteric coated aspirin. Arthritis Rheum 1983; 26: 46-50.
20. 20 Portek I, Graham G, Fleming A. Enteric coated pelletized aspirin. Gastrointestinal blood loss and bioavailability. Med J Aust 1981; 2: 39-40.
21. 21 Veys EM, Siron G, Coigne E, et al. Etude des pertes de sang occultes par la méthode au chrome radioactif au cours d'un traitement à I'acide acétylsalicylique. Enfluence de I'enrobage d'acétophtalate de cellulose. Pharm Acta Helv 1975; 50: 156-8.
22. 22 Hoftiezer JW, Burks M, Silvoso GR, Ivey KJ. Comparison of the effects of regular and enteric-coated aspirin on gastroduodenal mucosa of man. Lancet 1980; 2: 609-12.
23. 23 Lanza FL. A review of gastric ulcer and gastroduodenal injury in normal volunteers receiving aspirin and other non-steroidal anti-inflammatory drugs. Scand J Gastroenterol 1989; 24 (Suppl. 163): 24-31.
24. 24 Petroski D. A comparison of enteric-coated aspirin granules with plain and buffered aspirin: a report of two studies. Am J Gastroenterol 1986; 81: 26-8.
25. 25 Petroski D. Endoscopic comparison of various aspirin preparations - gastric mucosal adaptability to aspirin restudied. Curr Ther Res 1989; 45: 945-54.
26. 26 Savon JJ, Allen ML, DiMarino AJ, Hermann GA, Krum RP. Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration. Am J Gastroenterol 1995; 90: 581-5.
27. 27 Pritchard PJ, Kitchingman GK, Walt RP, et al. Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin. Br Med J 1989; 298: 493-6.
28. 28 Scarpignato C. Nonsteroidal anti-inflammatory drugs: How do they damage gastroduodenal mucosa? Dig Dis Sci 1995; 13 (Suppl. 1): 9-39.
29. 29 Hawkey CJ, Hawthorne AB, Hudson N, et al. Separation of the impairment of haemostasis by aspirin from mucosal injury in the human stomach. Clin Sci 1991; 81: 565-73.
30. 30 Schoen RT, Vender RJ. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med 1989; 86: 449-58.
31. 31 Sato Y, Asaka M, Takeda H, et al. The mechanisms of aspirin induced gastric mucosal injury. J Clin Gastroenterol 1993; 17: S2-4.
32. 32 Lichtenberger LM, Wang Z-M, Romero JJ. et al. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with Zwitterionic phospholipids: Insight into the mechanisms and reversal of NSAID-induced gastrointestinal injury. Nature Med 1995; 1: 154-8.
33. 33 Donelly MC, Hawkey CJ. COX-2 inhibitors - a new generation of safer NSAIDs. Aliment Pharmacol Ther 1997; 11: 227-36.
34. 34 Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre' double-blind, placebo-controlled trial. Lancet 1988; 2: 1277-80.
35. 35 Taha AAS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by non-steroidal anti-inflammatory drugs. N Engl J Med 1996; 334: 1435-9.
36. 36 Hawkey CJ, Karrasch JA. Szczepanski L, et al. for the OMNIUM Study Group. A comparison of omeprazole and misoprostol for treating and preventing ulcers associated with non steroidal anti-inflammatory drugs - the OMNIUM study. N Engl J Med 1998; 228: 727-34.
37. 37 Lanza FL. Endoscopic studies of gastric and duodenal injury after the use of ibuprofen, aspirin, and other nonsteroidal anti-inflammatory agents. Am J Med 1984; 77: 19-24.
38. 38 Somerville K, Faulkner G, Langman M. Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer. Lancet 1986; 1: 462-4.
39. 39 Langman MJS, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 1: 1075-8.
40. 40 Fries JF, Ramey DR, Singli G, et al. A re-evaluation of aspirin therapy in rhcumatiod arthritis. Arch Intern Med 1993; 310: 827-30.